Bone Marrow Transplantation - Table of Contents alert Volume 51 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 51, Issue 2 (February 2016) In this issue Editorial Reviews Commentaries Original Articles Letters To The Editor Corrigendum Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Editorial Top SNPs and prognosis of GvHD before HCT: any progress? M I Abu Zaid, S Paczesny and D B Miklos Bone Marrow Transplant 2016 51: 161-162; advance online publication, October 12, 2015; 10.1038/bmt.2015.240 Full Text Reviews Top Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives R Oostvogels, H M Lokhorst and T Mutis Bone Marrow Transplant 2016 51: 163-171; advance online publication, October 26, 2015; 10.1038/bmt.2015.256 Abstract | Full Text A risk-adapted approach to acute GVHD treatment: are we there yet? S G Holtan and M L MacMillan Bone Marrow Transplant 2016 51: 172-175; advance online publication, November 9, 2015; 10.1038/bmt.2015.261 Abstract | Full Text Childhood to adult transition and long-term follow-up after blood and marrow transplantation M C Cupit, C Duncan, B N Savani and S K Hashmi Bone Marrow Transplant 2016 51: 176-181; advance online publication, December 7, 2015; 10.1038/bmt.2015.228 Abstract | Full Text Commentaries Top Early and late graft-failure after transplants R P Gale Bone Marrow Transplant 2016 51: 182-183; advance online publication, November 2, 2015; 10.1038/bmt.2015.255 Full Text When is second allogeneic HSCT for relapse of acute leukaemia an option? M Christopeit Bone Marrow Transplant 2016 51: 184-185; advance online publication, December 7, 2015; 10.1038/bmt.2015.285 Full Text Original Articles Top ACUTE LEUKEMIA Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes R Vrhovac, M Labopin, F Ciceri, J Finke, E Holler, J Tischer, B Lioure, J Gribben, L Kanz, D Blaise, P Dreger, G Held, R Arnold, A Nagler and M Mohty on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant 2016 51: 186-193; advance online publication, October 5, 2015; 10.1038/bmt.2015.221 Abstract | Full Text T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes R Devillier, S Bramanti, S Fürst, B Sarina, J El-Cheikh, R Crocchiolo, A Granata, C Chabannon, L Morabito, S Harbi, C Faucher, A Santoro, P-J Weiller, N Vey, C Carlo-Stella, L Castagna and D Blaise Bone Marrow Transplant 2016 51: 194-198; advance online publication, November 9, 2015; 10.1038/bmt.2015.270 Abstract | Full Text Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome B J Trottier, Z Sachs, T E DeFor, L Shune, M Dolan, D J Weisdorf, C Ustun and E D Warlick Bone Marrow Transplant 2016 51: 199-204; advance online publication, November 23, 2015; 10.1038/bmt.2015.274 Abstract | Full Text LYMPHOMA Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma S Fuji, H Fujiwara, N Nakano, A Wake, Y Inoue, T Fukuda, M Hidaka, Y Moriuchi, T Miyamoto, N Uike, J Taguchi, T Eto, T Tomoyose, T Kondo, A Yamanoha, T Ichinohe, Y Atsuta, A Utsunomiya and ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation Bone Marrow Transplant 2016 51: 205-211; advance online publication, November 2, 2015; 10.1038/bmt.2015.265 Abstract | Full Text Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT L Sellner, A Boumendil, H Finel, S Choquet, G de Rosa, F Falzetti, R Scime, G Kobbe, F Ferrara, A Delmer, H Sayer, S Amorim, R Bouabdallah, J Finke, G Salles, I Yakoub-Agha, E Faber, E Nicolas-Virelizier, L Facchini, D Vallisa, E Zuffa, A Sureda and P Dreger on behalf of the EBMT Lymphoma Working Party Bone Marrow Transplant 2016 51: 212-218; advance online publication, November 16, 2015; 10.1038/bmt.2015.273 Abstract | Full Text INHERITED AND GENETIC DISORDERS Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study A A Hamidieh, M Behfar, Z Pourpak, S Faghihi-Kashani, M R Fazlollahi, A S Hosseini, M Movahedi, M Mozafari, M Moin and A Ghavamzadeh Bone Marrow Transplant 2016 51: 219-226; advance online publication, November 23, 2015; 10.1038/bmt.2015.277 Abstract | Full Text SOLID CANCERS Tandem high-dose chemotherapy with thiotepa and busulfan–melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients C Pasqualini, C Dufour, G Goma, M-A Raquin, V Lapierre and D Valteau-Couanet Bone Marrow Transplant 2016 51: 227-231; advance online publication, November 2, 2015; 10.1038/bmt.2015.264 Abstract | Full Text CONDITIONING Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis S Ben-Barouch, O Cohen, L Vidal, I Avivi and R Ram Bone Marrow Transplant 2016 51: 232-240; advance online publication, October 12, 2015; 10.1038/bmt.2015.238 Abstract | Full Text HISTOCOMPATIBILITY AND DONOR SELECTION ISSUES Geographic access to hematopoietic cell transplantation services in the United States P L Delamater and J P Uberti Bone Marrow Transplant 2016 51: 241-248; advance online publication, October 12, 2015; 10.1038/bmt.2015.246 Abstract | Full Text TRANSPLANT TOXICITIES The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function Y Kong, Y-T Wang, Y Hu, W Han, Y-J Chang, X-H Zhang, Z-F Jiang and X-J Huang Bone Marrow Transplant 2016 51: 249-255; advance online publication, October 5, 2015; 10.1038/bmt.2015.229 Abstract | Full Text A reappraisal of ICU and long-term outcome of allogeneic hematopoietic stem cell transplantation patients and reassessment of prognosis factors: results of a 5-year cohort study (2009–2013) L Platon, L Amigues, P Ceballos, N Fegueux, D Daubin, N Besnard, R Larcher, L Landreau, C Agostini, S Machado, O Jonquet and K Klouche Bone Marrow Transplant 2016 51: 256-261; advance online publication, November 16, 2015; 10.1038/bmt.2015.269 Abstract | Full Text The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation E J Ladas, M Bhatia, L Chen, E Sandler, A Petrovic, D M Berman, F Hamblin, M Gates, R Hawks, L Sung and M Nieder Bone Marrow Transplant 2016 51: 262-266; advance online publication, November 16, 2015; 10.1038/bmt.2015.275 Abstract | Full Text Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution E Brissot, F Rialland, X Cahu, M Strullu, N Corradini, C Thomas, N Blin, X Rialland, E Thebaud, P Chevallier, P Moreau, N Milpied, J L Harousseau, F Mechinaud and M Mohty Bone Marrow Transplant 2016 51: 267-272; advance online publication, December 7, 2015; 10.1038/bmt.2015.250 Abstract | Full Text GRAFT-VERSUS-HOST DISEASE The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD M Nadeau, S Perreault, S Seropian, F Foss, I Isufi and D L Cooper Bone Marrow Transplant 2016 51: 273-276; advance online publication, October 19, 2015; 10.1038/bmt.2015.247 Abstract | Full Text INFECTIONS Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis M L Riches, S Trifilio, M Chen, K W Ahn, A Langston, H M Lazarus, D I Marks, R Martino, R T Maziarz, G A Papanicolou, J R Wingard, J-AH Young and C L Bennett Bone Marrow Transplant 2016 51: 277-282; advance online publication, November 2, 2015; 10.1038/bmt.2015.263 Abstract | Full Text Letters To The Editor Top Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant A L Oh, P Patel, K Sweiss, R Chowdhery, S Dudek and D Rondelli Bone Marrow Transplant 2016 51: 283-285; advance online publication, October 5, 2015; 10.1038/bmt.2015.216 Full Text Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening J B L Lee, A Billen, R N Lown, M N Potter, C F Craddock, H de Lavallade, B E Shaw and C C Sharpe Bone Marrow Transplant 2016 51: 286-287; advance online publication, October 5, 2015; 10.1038/bmt.2015.224 Full Text Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors B K Mortensen, N Jacobsen, C Heilmann and H Sengeløv Bone Marrow Transplant 2016 51: 288-290; advance online publication, October 5, 2015; 10.1038/bmt.2015.231 Full Text Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma F L Locke, M Menges, T Nishihori, C Nwoga, M Alsina and C Anasetti Bone Marrow Transplant 2016 51: 291-294; advance online publication, October 12, 2015; 10.1038/bmt.2015.239 Full Text New-onset food allergy following cord blood transplantation in adult patients T Mori, J Kato, M Sakurai, N Hashimoto, S Kohashi, R Hashida, M Saburi, T Kikuchi, Y Yamane, K Hoshino and S Okamoto Bone Marrow Transplant 2016 51: 295-296; advance online publication, October 12, 2015; 10.1038/bmt.2015.243 Full Text Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation B Dhakal, R Brazauskas, C A Lara, P Hari, M Pasquini and A D’Souza Bone Marrow Transplant 2016 51: 297-299; advance online publication, October 12, 2015; 10.1038/bmt.2015.244 Full Text Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer A A Nelson, A M Harrington, S Kroft, M A Dahar, M Hamadani and B Dhakal Bone Marrow Transplant 2016 51: 300-302; advance online publication, October 12, 2015; 10.1038/bmt.2015.245 Full Text Pericardial effusion post transplantation predicts inferior overall survival following allo-hematopoietic stem cell transplant X Chen, Q Zou, J Yin, C Wang, J Xu, J Wei and Y Zhang Bone Marrow Transplant 2016 51: 303-306; advance online publication, October 19, 2015; 10.1038/bmt.2015.227 Full Text Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement A M Cornelison, R M Saliba, A Afrough, Y Dinh, Y Nieto, Q Bashir, N Shah, S Parmar, C Hosing, U Popat, E Shpall, R Champlin and M H Qazilbash Bone Marrow Transplant 2016 51: 307-309; advance online publication, October 19, 2015; 10.1038/bmt.2015.242 Full Text Pulmonary hypertension associated with bronchiolitis obliterans after hematopoietic stem cell transplantation A Pate, S Rotz, M Warren, R Hirsch, M Cash, K C Myers, J El-Bietar, A Nelson, G Wallace, A H Filipovich, J Bleesing, R S Chima, S M Davies, S Jodele and C E Dandoy Bone Marrow Transplant 2016 51: 310-312; advance online publication, October 19, 2015; 10.1038/bmt.2015.248 Full Text Characteristics and outcomes of aplastic anemia in HIV patients: a brief report from the severe aplastic anemia working party of the European Society of Blood and Bone Marrow Transplantation S Pagliuca, L Gérard, A Kulasekararaj, M Eapen, D Boutboul, H Martin, M A Salvino, C Knol-Bout, C Dufour, R Peffault de Latour and J Marsh Bone Marrow Transplant 2016 51: 313-315; advance online publication, October 19, 2015; 10.1038/bmt.2015.252 Full Text Unmanipulated haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with paroxysmal nocturnal hemoglobinuria and secondary aplastic anemia M Sarmiento and P A Ramírez Bone Marrow Transplant 2016 51: 316-318; advance online publication, October 26, 2015; 10.1038/bmt.2015.251 Full Text Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity S Garciaz, D Coso, J-M Schiano de Collela, F Broussais, A-M Stoppa, T Aurran, C Chabannon, A Helvig, L Xerri, D Blaise and R Bouabdallah Bone Marrow Transplant 2016 51: 319-321; advance online publication, November 2, 2015; 10.1038/bmt.2015.257 Full Text Corrigendum Top Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis M L Riches, S Trifilio, M Chen, K W Ahn, A Langston, H M Lazarus, D I Marks, R Martino, R T Maziarz, G A Papanicolou, J R Wingard, J-AH Young and C L Bennett Bone Marrow Transplant 2016 51: 322; 10.1038/bmt.2015.318 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.